Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints

MT Newswires Live12-11

Incyte (INCY) said Tuesday that late-breaking results from a phase 3 trial of tafasitamab, or Monjuvi, showed that it met a primary endpoint of progression-free survival, or PFS.

The study evaluated tafasitamab in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma, the company said.

Data show that the drug demonstrated "a statistically significant and clinically meaningful improvement" in PFS in 548 patients and that the benefit was consistent across all patient groups irrespective of the number of previous lines of therapy. The study also met key secondary endpoints including improvement in complete response, overall response rate, and duration of response, the company said.

The company added that it plans to file a supplemental biologics license application in the US for tafasitamab in follicular lymphoma by the end of 2024.

Price: 72.29, Change: +0.18, Percent Change: +0.25

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490904514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 00:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490904514","market":"sg","top_or_hot":-1,"title":"Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints","media":"MT Newswires Live","content":"<html><body><p> Incyte (INCY) said Tuesday that late-breaking results from a phase 3 trial of tafasitamab, or Monjuvi, showed that it met a primary endpoint of progression-free survival, or PFS.</p><p>The study evaluated tafasitamab in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma, the company said.</p><p>Data show that the drug demonstrated \"a statistically significant and clinically meaningful improvement\" in PFS in 548 patients and that the benefit was consistent across all patient groups irrespective of the number of previous lines of therapy. The study also met key secondary endpoints including improvement in complete response, overall response rate, and duration of response, the company said.</p><p>The company added that it plans to file a supplemental biologics license application in the US for tafasitamab in follicular lymphoma by the end of 2024.</p><p>Price: 72.29, Change: +0.18, Percent Change: +0.25</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 00:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Incyte (INCY) said Tuesday that late-breaking results from a phase 3 trial of tafasitamab, or Monjuvi, showed that it met a primary endpoint of progression-free survival, or PFS.The study evaluated ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490904514","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490904514","pubTimestamp":1733848071,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Incyte  said Tuesday that late-breaking results from a phase 3 trial of tafasitamab, or Monjuvi, showed that it met a primary endpoint of progression-free survival, or PFS.The study evaluated tafasitamab in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma, the company said.Data show that the drug demonstrated \"a statistically significant and clinically meaningful improvement\" in PFS in 548 patients and that the benefit was consistent across all patient groups irrespective of the number of previous lines of therapy. The study also met key secondary endpoints including improvement in complete response, overall response rate, and duration of response, the company said.The company added that it plans to file a supplemental biologics license application in the US for tafasitamab in follicular lymphoma by the end of 2024.Price: 72.29, Change: +0.18, Percent Change: +0.25","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4588":"碎股","INCY":"因塞特医疗","BK4532":"文艺复兴科技持仓"},"translate_title":"Incite表示Monjuvi在滤泡性淋巴瘤患者中的3期试验达到终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"Incyte (INCY) said Tuesday that late-breaking results from a phase 3 trial of tafasitamab, or Monjuvi, showed that it met a primary endpoint of progression-free survival, or PFS.The study evaluated tafasitamab in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma, the company said.Data show that the drug demonstrated \"a statistically significant and clinically meaningful improvement\" in PFS in 548 patients and that the benefit was consistent across all patient groups irrespective of the number of previous lines of therapy. The study also met key secondary endpoints including improvement in complete response, overall response rate, and duration of response, the company said.The company added that it plans to file a supplemental biologics license application in the US for tafasitamab in follicular lymphoma by the end of 2024.Price: 72.29, Change: +0.18, Percent Change: +0.25","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490904514"}